Pelthos Therapeutics Inc.
PTHS- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001919246
In the last 90 days, Pelthos Therapeutics Inc. insiders filed 0 open-market purchases and 3 sales; 24 institutions reported holding it in 13F filings for Q2 2026, worth $37.4M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Pelthos Therapeutics Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 5 | 14 | +9 |
| Shares | 147.9K | 462.8K | +314.9K (+212.9%) |
| Value | $187.3K | $13.0M | +$12.8M (+6,818.1%) |
New holders (10)
Institutions that held Pelthos Therapeutics Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Murchinson Ltd. | 280,000 | $7.84M | 1.52% |
| Vanguard Group Inc | 66,836 | $1.87M | 0.00% |
| Ikarian Capital, LLC | 62,451 | $1.75M | 0.40% |
| Boothbay Fund Management, LLC | 21,245 | $594.9K | 0.02% |
| Diadema Partners LP | 10,498 | $293.9K | 0.20% |
| Knott David M Jr | 6,112 | $171.1K | 0.07% |
| Persistent Asset Partners Ltd | 2,403 | $67.3K | 0.05% |
| Steward Partners Investment Advisory, LLC | 1,910 | $53.5K | 0.00% |
| JPMorgan Chase & Co | 1 | $28 | 0.00% |
| Citigroup Inc | 1 | $28 | 0.00% |
Sold out (1)
Institutions that held Pelthos Therapeutics Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Millennium Management LLC | 136,712 | $172.3K |